This info is pulled from their patent, talking about different delivery methods. (i.e via Vaxxas Nanopatch and others)
5.3 Routes of Administration
[0164] Once formulated, the compositions of the invention can be administered directly to the subject (e.g., as described above). Direct delivery of first and second construct- containing compositions in vivo will generally be accomplished with or without vectors, as described above, by injection using either a conventional syringe, needless devices such as BIOJECT™ or a gene gun, such as the ACCELL™ gene delivery system (PowderMed Ltd, Oxford, England) or microneedle device. The constructs can be delivered (e.g. , injected) intradermally. Delivery of nucleic acid into cells of the epidermis is particularly preferred as this mode of administration provides access to skin-associated lymphoid cells and provides for a transient presence of nucleic acid (e.g. , DNA) in the recipient. [0165] Suitably, the compositions described herein are formulated for NANOPASS
(Vaxxas, Brisbane, Australia) patch for microneedle administration.
[0166] In other embodiments the compositions of the invention are administered by electroporation. Such techniques greatly increases plasmid transfer across the cell plasma membrane barrier to directly or indirectly transfect plasmid into the cell cytoplasm. [0167] Additionally, biolistic delivery systems employing particulate carriers such as gold and tungsten, are especially useful for delivering the compositions of the present invention. The particles are coated with the synthetic expression cassette(s) to be delivered and accelerated to high velocity, generally under a reduced atmosphere, using a gun powder discharge from a "gene gun." For a description of such techniques, and apparatuses useful therefor, see, e.g., U.S. Pat. Nos. 4,945,050; 5,036,006; 5, 100,792; 5,179,022; 5,371,015; and 5,478,744. In illustrative examples, gas-driven particle acceleration can be achieved with devices such as those manufactured by PowderMed Pharmaceuticals PLC (Oxford, UK) and PowderMed Vaccines Inc. (Madison, Wis.), some examples of which are described in U.S. Pat. Nos. 5,846,796; 6,010,478; 5,865,796; 5,584,807; and EP Patent No. 0500 799. This approach offers a needle-free delivery approach wherein a dry powder formulation of microscopic particles, such as polynucleotide or polypeptide particles, are accelerated to high speed within a helium gas jet generated by a hand held device, propelling the particles into a target tissue of interest. Other devices and methods that may be useful for gas-driven needleless injection of compositions of the present invention include those provided by BIOJECT, Inc. (Portland, Oreg.), some examples of which are described in U.S. Pat. Nos. 4,790,824; 5,064,413; 5,312,335; 5,383,851 ; 5,399, 163; 5,520,639 and 5,993,412.
[0168] Alternatively, micro-cannula- and microneedle-based devices (such as those being developed by Becton Dickinson and others) can be used to administer the compositions of the invention. Illustrative devices of this type are described in EP 1 092 444 Al, and U.S. application Ser. No. 606,909, filed Jun. 29, 2000. Standard steel cannula can also be used for intra-dermal delivery using devices and methods as described in U.S. Ser. No. 417,671, filed
Oct. 14, 1999. These methods and devices include the delivery of substances through narrow gauge (about 30 G) "micro-cannula" with limited depth of penetration, as defined by the total length of the cannula or the total length of the cannula that is exposed beyond a depth-limiting feature. It is within the scope of the present invention that targeted delivery of substances including the compositions described herein can be achieved either through a single microcannula or an array of microcannula (or "microneedles"), for example 3-6 microneedles mounted on an injection device that may include or be attached to a reservoir in which the substance to be administered is contained.
(20min delay)